A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine

Shalonda K. Slater, Timothy D Nelson, Marielle A. Kabbouche, Susan L. Lecates, Paul Horn, Ann Segers, Paula Manning, Scott W. Powers, Andrew D. Hershey

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial. Background: CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults. Methods: One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100-mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed. Results: Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)-=-15.68, p-<-0.001], severity [F(1, 54)-=-8.09, p-=-0.006], and duration [F(1, 45)-=-6.27, p-=-0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)-=-2.34, p->-0.05], severity [F(1, 54)-=-0.06, p->-0.05], or duration [F(1, 45)-=-0.14, p->-0.05]. Conclusions: Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10-may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.

Original languageEnglish (US)
Pages (from-to)897-905
Number of pages9
JournalCephalalgia
Volume31
Issue number8
DOIs
StatePublished - Jun 1 2011

Fingerprint

coenzyme Q10
Migraine Disorders
Placebos
Pediatrics
Headache

Keywords

  • CoQ10
  • Headaches
  • pain
  • pediatric disorders

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. / Slater, Shalonda K.; Nelson, Timothy D; Kabbouche, Marielle A.; Lecates, Susan L.; Horn, Paul; Segers, Ann; Manning, Paula; Powers, Scott W.; Hershey, Andrew D.

In: Cephalalgia, Vol. 31, No. 8, 01.06.2011, p. 897-905.

Research output: Contribution to journalArticle

Slater, SK, Nelson, TD, Kabbouche, MA, Lecates, SL, Horn, P, Segers, A, Manning, P, Powers, SW & Hershey, AD 2011, 'A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine', Cephalalgia, vol. 31, no. 8, pp. 897-905. https://doi.org/10.1177/0333102411406755
Slater, Shalonda K. ; Nelson, Timothy D ; Kabbouche, Marielle A. ; Lecates, Susan L. ; Horn, Paul ; Segers, Ann ; Manning, Paula ; Powers, Scott W. ; Hershey, Andrew D. / A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. In: Cephalalgia. 2011 ; Vol. 31, No. 8. pp. 897-905.
@article{1f054b20575544288feb1ee8d79a2758,
title = "A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine",
abstract = "Objective: To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial. Background: CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults. Methods: One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100-mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed. Results: Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)-=-15.68, p-<-0.001], severity [F(1, 54)-=-8.09, p-=-0.006], and duration [F(1, 45)-=-6.27, p-=-0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)-=-2.34, p->-0.05], severity [F(1, 54)-=-0.06, p->-0.05], or duration [F(1, 45)-=-0.14, p->-0.05]. Conclusions: Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10-may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.",
keywords = "CoQ10, Headaches, pain, pediatric disorders",
author = "Slater, {Shalonda K.} and Nelson, {Timothy D} and Kabbouche, {Marielle A.} and Lecates, {Susan L.} and Paul Horn and Ann Segers and Paula Manning and Powers, {Scott W.} and Hershey, {Andrew D.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1177/0333102411406755",
language = "English (US)",
volume = "31",
pages = "897--905",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine

AU - Slater, Shalonda K.

AU - Nelson, Timothy D

AU - Kabbouche, Marielle A.

AU - Lecates, Susan L.

AU - Horn, Paul

AU - Segers, Ann

AU - Manning, Paula

AU - Powers, Scott W.

AU - Hershey, Andrew D.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Objective: To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial. Background: CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults. Methods: One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100-mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed. Results: Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)-=-15.68, p-<-0.001], severity [F(1, 54)-=-8.09, p-=-0.006], and duration [F(1, 45)-=-6.27, p-=-0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)-=-2.34, p->-0.05], severity [F(1, 54)-=-0.06, p->-0.05], or duration [F(1, 45)-=-0.14, p->-0.05]. Conclusions: Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10-may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.

AB - Objective: To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial. Background: CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults. Methods: One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100-mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed. Results: Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)-=-15.68, p-<-0.001], severity [F(1, 54)-=-8.09, p-=-0.006], and duration [F(1, 45)-=-6.27, p-=-0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)-=-2.34, p->-0.05], severity [F(1, 54)-=-0.06, p->-0.05], or duration [F(1, 45)-=-0.14, p->-0.05]. Conclusions: Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10-may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.

KW - CoQ10

KW - Headaches

KW - pain

KW - pediatric disorders

UR - http://www.scopus.com/inward/record.url?scp=79958812541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958812541&partnerID=8YFLogxK

U2 - 10.1177/0333102411406755

DO - 10.1177/0333102411406755

M3 - Article

VL - 31

SP - 897

EP - 905

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 8

ER -